Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.33), $0.12 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $69.75 million.

– LINZESS® (linaclotide) U.S. net sales grew to $148 million in 1Q 2017, primarily driven by more than 20% growth in LINZESS volume year-over-year –

– Three LINZESS doses now available with the introduction of 72 mcg dose –

– Multiple 2017 pipeline catalysts expected, including IW-3718 Phase IIb data for uncontrolled GERD and DUZALLO™ approval

2017 Financial Guidance

• Ironwood continues to expect:
  • R&D expenses to be in the range of $145 million to $160 million.
  • SG&A expenses to be in the range of $235 million to $250 million.
  • the combined Allergan and Ironwood total 2017 marketing and sales expenses for LINZESS to be in the range of $250 million to $280 million.
  • net interest expense to be approximately $40 million.
  • to use less than $100 million in cash for operations in 2017.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.